Q4 2024 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Key Points
- Sartorius Stedim Biotech SA (SDMHF) achieved its reverse guidance for 2024, with both top-line and profitability meeting expectations.
- The consumables business showed strong growth towards the end of the year, contributing positively to sales.
- Order intake for the company increased by double digits, driven by strong demand for consumables.
- The company successfully implemented an efficiency program in 2024, which helped maintain a robust EBITDA margin of 28.0%.
- Sartorius Stedim Biotech SA (SDMHF) expects profitable growth in 2025, with a focus on outperforming market growth rates.
- Sales for the Bioprocess Solutions division were only slightly above the previous year's level, with equipment sales remaining muted.
- The LPS division experienced a decline in sales, particularly due to a weak market in China.
- Profitability was slightly below 2023 levels, despite being robust, indicating some margin pressure.
- The company remains cautious about the market outlook for 2025, expecting growth below midterm average rates.
- The financial results were impacted by increased depreciation and higher financial expenditures, leading to a lower underlying net profit compared to the prior year.
Ladies and gentlemen, welcome to the Sartorius and Sartorius Stedim Biotech Conference Call on the preliminary results 2024 conference call and live webcast. I am Yousef, the Chorus Call operator. (Operator Instructions) The conference is being recorded. This call is scheduled for 60 minutes. The presentation will be followed by a Q&A session. (Operator Instructions) The conference was not to be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Dr. Joachim Kreuzburg. Please go ahead.
Yeah. Thank you very much for opening our conference call today, and welcome, everyone. Thank you for dialing in. Thank you for your interest in Sartorius and Sartorius Stedim Biotech. As always, we will present our results in a way that I will start with some highlights, and then Florian will expand on the financial results in quite some detail on the Sartorius Group. And then after that, Rene will talk about the results
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
